Matthew Carson

Dr. Matthew Carson


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Annual Review of Pathology: Mechanisms of Disease
Verified
Journal Article
Open access
MCMatthew Carson
Matthew Carson
KNKari Nejak-Bowen
Kari Nejak-Bowen
The liver has a critical role in regulating host metabolism, immunity, detoxification, and homeostasis. Proper liver function is essential for host health, and dysregulation of hepatic signaling pathways can lead to the onset of disease. The Wnt/β-catenin signaling pathway is an important regulator of liver homeostasis and function. Throughout life, hepatic Wnt/β-catenin signaling contributes to liver development and growth, metabolic zonation, and regeneration. Extensive research has demonstrated that aberrant Wnt/β-catenin signaling drives liver pathologies, including cancers, steatohepatitis, and cholestasis. In this review, we discuss the Wnt/β-catenin pathway as it pertains to liver function and how disruptions in this pathway contribute to the onset and progression of liver diseases. Further, we discuss ongoing research that targets the Wnt/β-catenin pathway for the treatment of liver pathologies.

1 July 2024 in Hepatology Communications
Verified
Journal Article
Open access
OBOluwashanu Balogun
Oluwashanu Balogun
DSDaniel Shao
Daniel Shao
MCMatthew Carson
Matthew Carson
TKThalia King
Thalia King
KKKaris Kosar
Karis Kosar
KNKari Nejak-Bowen
Kari Nejak-Bowen
Background: Cholestasis is an intractable liver disorder that results from impaired bile flow. We have previously shown that the Wnt/β-catenin signaling pathway regulates the progression of cholestatic liver disease through multiple mechanisms, including bile acid metabolism and hepatocyte proliferation. To further explore the impact of these functions during intrahepatic cholestasis, we exposed mice to a xenobiotic that causes selective biliary injury. Methods: α-naphthylisothiocyanate (ANIT) was administered to liver-specific knockout (KO) of β-catenin and wild-type mice in the diet. Mice were killed at 6 or 14 days to assess the severity of cholestatic liver disease, measure the expression of target genes, and perform biochemical analyses. Results: We found that the presence of β-catenin was protective against ANIT, as KO mice had a significantly lower survival rate than wild-type mice. Although serum markers of liver damage and total bile acid levels were similar between KO and wild-type mice, the KO had minor histological abnormalities, such as sinusoidal dilatation, concentric fibrosis around ducts, and decreased inflammation. Notably, both total glutathione levels and expression of glutathione-S-transferases, which catalyze the conjugation of ANIT to glutathione, were significantly decreased in KO after ANIT. Nuclear factor erythroid-derived 2-like 2, a master regulator of the antioxidant response, was activated in KO after ANIT as well as in a subset of patients with primary sclerosing cholangitis lacking activated β-catenin. Despite the activation of nuclear factor erythroid-derived 2-like 2, KO livers had increased lipid peroxidation and cell death, which likely contributed to mortality. Conclusions: Loss of β-catenin leads to increased cellular injury and cell death during cholestasis through failure to neutralize oxidative stress, which may contribute to the pathology of this disease.

9 March 2026 in The FASEB Journal
Verified
Journal Article
Open access
BHBrooke Hutchison
Brooke Hutchison
JFJamie Fornsaglio
Jamie Fornsaglio
RCRidgeway Case
Ridgeway Case
PCPam Cornuet
Pam Cornuet
FQFu‐Ying Qin
Fu‐Ying Qin
MCMatthew Carson
Matthew Carson
The gut‐liver axis is the bidirectional relationship between the gut microbiota and the liver. Dysbiosis in the gut‐liver axis and disrupted bile acid homeostasis contribute to cholestatic liver disease pathogenesis. Patients afflicted with cholestasis have accelerated bone loss, a higher incidence of fractures, and are at risk of developing osteoporosis. However, the mechanisms underlying bone loss are largely unknown. The study purpose was to investigate the role of the gut‐liver axis and bile acid signaling on skeletal homeostasis during cholestasis. Male C57BL/6J specific‐pathogen‐free mice were administered 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine from age 11 to 15 weeks to induce cholestasis. 16s rDNA sequencing was performed on colonic contents. Livers were processed for qRT‐pCR. Trabecular and cortical bone were analyzed by micro‐CT. Osteoclast/osteoblast outcomes were determined by histomorphometry. Bile acid concentrations in serum and bone marrow were assessed by mass spectrometry. MC3T3‐E1 and RAW 264.7 cells were stimulated with bile acids at concentrations found in the bone marrow to determine their effects on osteoblasts and osteoclasts. Cholestatic mice had less bone mass than controls, attributed to increases in osteoclasts and decreases in osteoblasts. Following cholestatic injury, mice show dysbiotic shifts in their colonic bacteriome, increased expression of hepatic bile acid efflux transporters, and elevated bone marrow bile acids. In vitro, bile acids from the bone marrow of cholestatic mice suppressed osteoblastogenesis and promoted osteoclastogenesis, which was rescued by stimulating cells with a farnesoid X receptor agonist. This study introduces the gut‐liver axis as a novel regulator of skeletal homeostasis during cholestatic liver disease through dysregulated bile acid signaling.

25 September 2026 in The American Journal of Pathology
Verified
Journal Article
Open access
VLVeronica Lee
Veronica Lee
CCChun Cheng Chiang
Chun Cheng Chiang
OBOluwashanu Balogun
Oluwashanu Balogun
PCPamela Cornuet
Pamela Cornuet
MCMatthew Carson
Matthew Carson
KNKari Nejak-Bowen
Kari Nejak-Bowen